Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1

AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):249-53. doi: 10.1089/aid.1998.14.249.


We compared the development of resistance toward BI-RG-587 (nevirapine) and alpha-APA R89439 (loviride) starting from the wild-type HIV-1 strain IIIB and the 3TC-resistant HIV-1 strain containing the M184V mutation. The reverse transcriptase of the M184V mutant has been reported to have a higher fidelity. Our experiments showed that there was no significant delay in virus breakthrough of the M184V mutant as compared with the wild-type virus. We therefore conclude that the reported higher fidelity of the M184V mutant does not lead to a delay in the development of resistance to the nonnucleoside reverse transcriptase inhibitors nevirapine and loviride.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / pharmacology
  • Acetophenones / pharmacology
  • Anti-HIV Agents / pharmacology*
  • Cells, Cultured
  • Cytopathogenic Effect, Viral
  • Drug Resistance, Microbial
  • Genes, Viral
  • HIV Reverse Transcriptase / genetics*
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Lamivudine / pharmacology*
  • Microbial Sensitivity Tests
  • Mutation
  • Nevirapine / pharmacology
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Sequence Analysis, DNA
  • Virus Replication / drug effects


  • Acetamides
  • Acetophenones
  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • loviride
  • Nevirapine
  • HIV Reverse Transcriptase